BIOGEN INC.

Key metrics

Financial performance

Over the last 9 fiscal years BIOGEN INC.'s revenue declined from $11.45B to $9.89B, a compound annual decline rate of 1.6%. Net profit margin compressed from 32.3% to 13.1% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (2,690 filings)

Recent press releases

• Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy2026-06-04

  Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy | Biogen

• UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus2026-06-01

  UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus | Biogen

• Biogen to Report First Quarter 2026 Financial Results April 29, 20262026-04-29

  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com . An archived version of the webcast will be available for at least 90 days following the presentation.

• Postpartum Depression Caitlins Story

Similar companies

The largest companies sharing BIOGEN INC.'s SEC industry classification (biological products, (no diagnostic substances)).